Harmony Biosciences Holdings (HRMY) Liabilities and Shareholders Equity (2019 - 2026)

Harmony Biosciences Holdings has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $1.3 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 20.49% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 billion (up 26.51% YoY) and the FY2025 annual result came in at $1.3 billion, up 27.26% from the prior year.
• Liabilities and Shareholders Equity held at $1.3 billion in Q1 2026 per HRMY's latest filing, from $1.3 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.3 billion in Q1 2026 and troughed at $464.0 million in Q1 2022.
• A 5-year average of $876.4 million and a median of $847.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 64.53% in 2022, then gained 12.92% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $673.9 million in 2022, then grew by 20.42% to $811.4 million in 2023, then rose by 23.14% to $999.2 million in 2024, then gained by 27.26% to $1.3 billion in 2025, then gained by 0.02% to $1.3 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.3 billion, $1.3 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.